For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 6 results
Author Title [ Type(Asc)] Year
Filters: Author is Ozorowski, Gabriel  [Clear All Filters]
Journal Article
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al..  2015.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.
Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al..  2018.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.
Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, Cottrell CA, Klasse PJ, Ward AB, Moore JP.  2018.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers .. J Virol. 92(13)
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2018.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.